GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Total Inventories

Cerus (CERS) Total Inventories : $39.9 Mil (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Total Inventories?

Cerus's total inventories for the quarter that ended in Dec. 2023 was $39.9 Mil. Cerus's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $41.3 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cerus's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cerus's Days Inventory for the three months ended in Dec. 2023 was 180.95.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cerus's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.50.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cerus's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.


Cerus Total Inventories Historical Data

The historical data trend for Cerus's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Total Inventories Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.49 23.25 26.79 29.00 39.87

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.00 36.61 40.61 42.66 39.87

Cerus Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Cerus  (NAS:CERS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cerus's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(65.852+0.75 * 35.5+0.5 * 39.868-144.304
-0-0.794)/181.248
=-0.18

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cerus's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=41.2645/20.809*365 / 4
=180.95

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cerus's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=20.809 / 41.2645
=0.50

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cerus's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=41.2645 / 46.768
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Cerus Total Inventories Related Terms

Thank you for viewing the detailed overview of Cerus's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451